Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Following the success of the 2016 pilot event we are pleased to announce the second edition of the HFA Career Cafe at Heart Failure 2017!
In a relaxed atmosphere, with a cup of coffee or tea, young heart failure enthusiasts are given the opportunity to meet internationally renowned experts in the field.
Applications open from 17 - 23 March (midnight CET)
The HFA Career Cafe is the meeting place for the future generation of heart failure specialists to interact with the great leaders of their specialty.
During individual interviews of 12 minutes, the selected applicants had the privilege to seek career development advice and recommendations from renowned professionals with years of successful careers behind them.
This is a unique platform where long-lasting generational relationships are possible!
Applications are done online and are free. Applicants are asked to select the mentors they wish to meet in order of preference.
All applicants have to be:
In the online application process, you will be asked to select the mentors you wish to meet in order of preference.
In total, 20 applicants will be selected based on their motivations and CV. Each applicant will be assigned up to 3 interviews.
Priority will be given to HFA Gold & Silver Members.
Become a member now.
ATTENTION: Applicants must be sure to not have another role (Moderated Poster, etc) planned during this timeslot to avoid conflicts.
Area of expertise: heart failure, trials, pathophysiology, cachexia
Stefan D. Anker is Professor of Innovative Clinical Trials (W3) at University Medicine Göttingen (from September 2014). Dr. Anker studied medicine at Charité Berlin and then started his clinical training in Germany completing it in the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993). He went on to earn a Ph.D. (1998) at the National Heart & Lung Institute of Imperial College London. Dr Anker was Professor of Cardiology & Cachexia Research (W2) at Charité Berlin (2002-14).
Dr. Anker has authored more than 700 original papers, reviews, and editorials that are well cited (total citations: >45,000, h-index: 104; source: Scopus, February 2017). For his work Dr. Anker has won several prizes (including 2 AHA-YIAs), and has obtained a number of fellowships and grants, including 2 NIH grants, 2 EU-FP7 grants & 1 IMI/Horizon2020 grant.
Dr. Anker is Vice President for National Cardiac Societies of the Board European Society of Cardiology (ESC, 2016-18). Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President (2012-14). Dr. Anker is founding Editor-in-Chief of the first open access heart failure journal ESC Heart Failure. Dr. Anker serves on the editorial boards of 5 scientific journals (including European Heart Journal, European Journal of Heart Failure & IJC).
Dr. Anker was and is member of >25 international clinical trial steering committees, chairing or co-chairing several (incl. FAIR-HF & FAIR-HF2, TIM-HF, AUGMENT-HF, RESHAPE-HF2, IMPULSE-HF and BACH). He served in a number of DMC’s (chairing 4) and end-point committees (chairing 4).
Area of expertise: acute and chronic heart failure, left ventricular healing and remodelling, peripartum cardiomyopathy, translational studies.
Professor Bauersachs studied Medicine at the University of Freiburg. After training as Clinical and Research Fellow at the Universities of Frankfurt and Heidelberg/Mannheim, in 1999 he moved to the University Hospital Wuerzburg where he became Consultant and Lecturer in Internal Medicine and Cardiology and was Associate Professor in the Department of Medicine from 2008 to 2010. Since 2010 he is Full Professor and Director of the Department of Cardiology and Angiology at Hannover Medical School.
Professor Bauersachs is an interventional cardiologist with special interests in acute coronary syndromes, left ventricular healing and remodelling, acute and chronic heart failure, as well as intensive care. He is particularly interested in the pathophysiology and treatment of peripartum cardiomyopathy, in aldosterone and mineralocorticoid receptor-mediated mechanisms, and the role of non-coding RNAs. He is Study Chair of the DIGIT-HF study investigating the effect of Digitoxin on morbidity/mortality in patients with advanced heart failure.
Professor Bauersachs is Fellow and Board Member of the Heart Failure Association (HFA) of the ESC, Chair of the HFA Study Group on Peripartum Cardiomyopathy, and Past Chair of the Working Group on Myocardial Function. He is Chair of the Cardiovascular Section of the Fachkollegium Medizin, Deutsche Forschungsgemeinschaft (DFG), Member of the Steering Committee of the DFG-funded Cluster of Excellence REBIRTH, and Speaker of the Clinical Research Group (KFO) 311 “(Pre-)terminal heart and lung failure - mechanical unloading and repair” funded by the DFG.
Area of expertise: Myocardial and ventricular function (contraction, relaxation and filling, non-uniformity) in health and disease, in particular in heart failure, including the role of cardiac endothelium in endothelial-cardiomyocyte cell communication.
Dirk L Brutsaert is a Professor-Emeritus in the Departments of Cardiology and Pharmacology at the University of Antwerp. Between 1966 and 2002 he served as a Professor of Physiology and Medicine in the Department of Medicine at the University of Antwerp; from 1981 to 2002 he was Co-Chairman of the Department of Cardiology at University Hospital Antwerp; and he was an Honorary Consultant in the Department of Cardiology at AZ Middelheim Hospital, University of Antwerp, until 2006.
Professor Brutsaert is Past President of the Heart Failure Association of the European Society of Cardiology (ESC) and of the Royal Academy of Medicine of Belgium (both 2004–2006).
Area expertise: exercise physiology, the possible role of oxygen therapy for heart failure and the natural history of heart failure.
Professor Andrew Clark is professor of clinical cardiology in the University of Hull. He was educated at Pembroke College, Cambridge, and trained in medicine at Westminster Medical School. He trained in heart failure at the National Heart and Lung Institute and Glasgow Western Infirmary. He has published widely on aspects of heart failure, and is co-editor of the Oxford Textbook of Heart Failure. He is the past Chair of the British Society for Heart Failure.
Area of expertise: heart failure, extending from its epidemiology and prevention, through the development and implementation of guidelines for the application of current knowledge, to large randomized trials. Particular current interests include the influence of myocardial and renal substrate on therapeutic response, novel methods of delivering care and theranostics.
Arno W. Hoes studied medicine at the Radboud University Nijmegen. He obtained his PhD degree at Erasmus University Rotterdam and was trained in Clinical Epidemiology at Erasmus Medical Center Rotterdam and the London School of Hygiene and Tropical Medicine.
In 1998 he was appointed professor of Clinical Epidemiology and General Practice at the Julius Center for Health Sciences and Primary Care of the University Medical Center in Utrecht. Since 2010, he is the Chair of the Julius Center.
His clinical research topics include the diagnosis, prognosis and therapeutic interventions in cardiovascular disease, and, in particular, heart failure. Many of his studies in heart failure are conducted in the primary care setting and focus on improving early diagnosis and prognosis of heart failure.
He is involved in many ESC activities and especially the HFA: he is a board member of the HFA and chairs its Patient Care Committee. Professor Hoes has been (co-)applicant of many research grants. He has (co-)authored over 500 papers in peer-reviewed journals (Hirsch index 68) and more than 50 PhD students completed their PhD thesis under his supervision.
Prof. Dr. Tiny Jaarsma (RN NFESC FAHA FAAN) is a professor in caring sciences/nursing science at the Faculty of Medicine and Health Sciences of the University of Linköping, Sweden. Her research focuses on the consequences of heart failure for patients and their families and developing and testing interventions to enhance their self-care. Her research has been published in over 300 publications ranging from short practical communications, book chapters to scientific publications in peer reviewed journals.
Tiny Jaarsma was trained as a nurse in Groningen, (NL) and she worked with cardiac patients since 1988, on the cardiology ward and in the Heart Failure clinic. She received her master degree from the University of Maastricht in 1992, as part of a nurse fellowship of the Netherlands Heart Foundation. She studied 6 months at the UCLA in 1993 with prof Dracup and completed her doctoral degree in 1999, with a thesis entitled “heart failure: nurses’ care”.
Currently she is the principle investigator of the ‘HF-WII’ study, an RCT on the effect of exergaming to increase physical activity in patients with heart failure. Her other research is aimed at improving communication between health care providers and patients regarding end of life issues (TALK-HF) Together with prof Anna Strömberg she is currently leading a research team with junior and senior researchers, international postdoc. She is the editor-in chief of the European Journal of Cardiovascular Nursing and the chair of the Science Committee of the ESC Council of Cardiovascular Nursing and Allied Professionals, involved in the Nursing Council of the AHA and is a former board member of the Heart Failure Association of the ESC. Professional activities include membership of national and international committees and guidelines (ESC, AHA), reviewer and member of editorial boards of peer-reviewed journals.
Area of expertise: pharmacology of heart failure, neuro-hormones in heart failure, genetics of dilated and hypertrophic cardiomyopathy.
Michel Komajda is the Head of the Department of Cardiology, Pitié Salpêtrière Hospital (Paris) and of the cardio-metabolic division (2006-2014). He is Professor of Cardiology at the University Pierre et Marie Curie - Paris VI since 1990. He is also member of the research Unit INSERM UMRS 1166, of the Institut Hospitalo-Universitaire ICAN and of the Academie Nationale de Medecine. He is past President of the European Society of Cardiology (2012-2014), and did his term as President of this organization in 2010-2012. He occupied several key positions including Vice-President of the ESC Working Groups, Association and Councils (2006-2008), and Chairman of the ESC Programme Committee in 2005-2006 in the ESC. He was also Co-Chairman on the “Euro Heart Failure Survey I” and Member of the Executive Committee of “Euro Heart Failure Survey II” Programmes. He occupied the positions of Treasurer and General Secretary of the French Society of Cardiology and was President of this Society in 2002-2003. He is member of the Scientific Board of Acta Cardiologica, member of the Editorial Boards of European Heart Journal, European Journal of Heart Failure, Heart, and International Journal of Cardiology. Michel Komajda is the author of over 300 peer-reviewed papers, mostly in heart failure and has collaborated in several Steering and Executive Committees of international trials on heart failure and cardiovascular diseases (CARMEN, COMET, I-PRESERVE, HEAAL, RECORD, CORONA, SHIFT).
Area of expertise: Heart failure, Cardio-Oncology and Takotsubo syndrome
Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. Dr Lyon is a current member of the HFA board and chair of the HFA Cardio-Oncology and Takotsubo Syndrome Study Groups. Dr Lyon is president of the British Cardio-Oncology Society which is hosting the Global Cardio-Oncology Summit in London in September 2017. Dr Lyon studied Medicine at Oxford University and he completed his PhD in gene therapy for heart failure at Imperial College London.
Lars H Lund, MD PhD, is an Associate Professor in the Department of Medicine, Karolinska Institutet, and Senior Consultant in the Department of Cardiology, Karolinska University Hospital. He trained in medicine, cardiology and heart failure at Duke University and Columbia University. His expertise is HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilization of existing evidence based interventions in heart failure with reduced ejection fraction and advanced heart failure, such as devices and transplantation, as well as in novel interventions and pragmatic trials of new use applications of existing drugs in heart failure with preserved ejection fraction. He has extensive experience and leadership positions in heart failure registries: He is Associate Director of the Swedish Heart Failure Registry (SwedeHF) Research Program; a board member of the Heart Failure Association (HFA) and a member of the working group for the HFA European Heart Failure Registry of the ESC Observational Research Program (EORP); chairman of the Executive Committee of the ESC HF Long-Term Regsitry, Associate Director the International Society for Heart & Lung Transplantation (ISHLT) Registry, and on the Steering Committee of the ISHLT International Registry for Mechanical Circulatory Support (IMACS). He is on steering committees for several trials and observational studies. He is or has been Associate Editor for and on the Editorial Boards of numerous journals including Circulation, European Journal of Heart Failure and Journal of Cardiac Failure. He has over 150 publications in peer reviewed journals, an H-index of 30, and one patent.
Area of expertise: pathophysiology and medical treatment of heart failure.
Christoph Maack is a Heisenberg Professor for Cardiovascular Physiology and Bioenergetics and a Senior Physician at the Department of Cardiology at the University of the Saarland in Homburg, Germany. His research focusses on the pathophysiology and treatment of heart failure, with a special focus on metabolic aspects and myocardial function. For his research, Professor Maack was awarded the Albert-Fraenkel- (2014) and the Arthur-Weber Awards (2015) of the German Cardiac Society, respectively. He was a Board member of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) from 2010-2016. From 2011-2014 he was the Coordinator of the Translational Research Committee of the HFA, and from 2014-2016 served on the Executive Committee of the HFA Board as the Chair of the Basic Science section. From 2013-2016, he organized the HFA Winter Meeting on Basic and Translational Research in Les Diablerets, Switzerland. Since 2015 he serves on the Programm Committee of the German Cardiac Society.
Prof. McDonagh completed her general medical training in Edinburgh. She was then a Research Fellow in Cardiology at the Western Infirmary in Glasgow from 1991-1994 and a Lecturer at the CRI in Heart Failure, University of Glasgow (Honorary Senior Registrar) from 1994-1999. Working on the epidemiology of Left Ventricular Dysfunction and Natriuretic Peptides with Professor Henry J Dargie.Subsequently she was appointed as a Senior Lecturer (Honorary Consultant Cardiologist) at the University of Glasgow and Glasgow Royal Infirmary where she ran the Heart Failure Service and was the Cardiologist involved in the Heart Transplant Programme (1999-2004). She was appointed as a Consultant Cardiologist with an Interest in Heart Failure at the Royal Brompton Hospital, London (2004-2011) before moving to King's College Hospital as a Consultant Cardiologist and Professor of Heart Failure.Her research interests are in clinical heart failure in particular the epidemiology of heart failure and left ventricular dysfunction and the role of biomarkers.
John McMurray BSc (Hons) MB ChB (Hons) MD FRCP FESC FACC FAHA FRSE FMedSci is Professor of Medical Cardiology and Deputy Director (Clinical) of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. He was the inaugural Eugene Braunwald Scholar in Cardiovascular (CV) Disease at the Brigham and Women’s Hospital, Boston, USA, and visiting Professor of Medicine, Harvard University, Boston, in 2010/2011 and is a Past-President of the Heart Failure Association of the European Society of Cardiology (ESC).
Professor McMurray’s primary research interest is in heart failure (HF) and his main research activity is clinical trials. He is, or was, the principal investigator, and member of the executive committee or steering committee in a number of large trials in HF, other CV diseases, renal disease and diabetes.
Professor McMurray sits on the editorial board of the New England Journal of Medicine, as well as several leading CV journals, including the European Heart Journal and European Journal of Heart Failure. He has published over 750 original papers, reviews, and book chapters and is the primary author or editor of 13 books and has a H-index of 152 (see: https://scholar.google.co.uk/citations?user=n0ZdRMoAAAAJ&hl=en). Professor McMurray was included in the 2015 and 2016 listings of Highly Cited Researchers by Thomson-Reuters (see: http://thomsonreuters.com/en/articles/2015/research-elite-2015-highly-cited-researchers.html)
Professor McMurray was the lead author of the World Health Organization and first Scottish Intercollegiate Guidelines Network Guidelines on the Management of HF. In addition he was a member of the 2008 ESC HF Guidelines Task Force, and Chair of the 2012 Task Force and member of the 2013 American College of Cardiology/American Heart Association HF Guidelines Committee and the 2014 National Institute for Health and Care Excellence (NICE) Acute HF Guideline Committee. He is a member of NICE Appraisal Committee A. In July 2015, Professor McMurray and Professor Salim Yusuf (McMaster University, Hamilton Ontario, Canada) were jointly awarded the 8th Arrigo Recordati International Prize for Scientific Research (for outstanding contributions in secondary prevention and risk reduction strategies in patients with cardiovascular diseases).
Prof. Alexandre Mebazaa is Professor of Anaesthesiology and Critical Care Medicine at the Hôpital Lariboisière, University Paris 7, France. Prof. Mebazaa qualified from the Louis Pasteur University, Strasbourg, France, and subsequently obtained a doctorate on the effect of endothelial cells on the calcium responsiveness of the cardiac myofilament from the Lariboisière School of Medicine, Paris. His research interests include mechanisms of contractile impairment during acute heart failure. He acted as member or Chair of several Steering Committee of agents tested in acute heart failure setting. He is also heavily involved in several European and global registries on circulatory failure. He authored or coauthored more than 300 papers and is Lead Editor of the “Acute Heart Failure” book. He is acting as Chair of Department of Anesthesiology and Critical Care in Paris
Area of expertise: early diagnosis and management of patients with acute heart failure; early diagnosis and management of patients with acute myocardial infarction; and improving patient care by integrating novel biochemical and electrocardiographic signatures.
Dr. Mueller is a clinical cardiologist at the University Hospital Basel. He is professor of cardiology, internal medicine and intensive care medicine at Basel University and head of the Cardiovascular Research Institute Basel (CRIB).
Prof. Ponikowski is currently Head of Department of Heart Diseases at Wroclaw Medical University and Head of Cardiology Department at the Military Hospital in Wroclaw. He holds a MD and a PhD from Wroclaw Medical University. He is a world recognized expert in the field of heart failure, he is member of the Committee for Practice Guidelines and chairperson of new ESC guidelines HF 2016. He has been involved in European Society of Cardiology activities since 1998, when he was elected as a Fellow (FESC). He acted as Past-President of Heart Failure Association of the ESC in the years 2010-12. He is the author of more than 550 publications which are well cited (h-index-83). He has been a principal investigator in more than 70 clinical trials, and a member of executive/steering committees in more than 20 clinical trials.
Dr Jillian Riley is a lecturer at the National Heart and Lung Institute, Imperial College. She directed studies in Cardio respiratory Nursing at the college for ten years before deciding to concentrate on supporting health professionals more widely to deliver high quality patient care.
With a particular interest in supporting the delivery of cardiac care Dr Riley was involved in the development of the UK National Service Framework for Coronary Heart Disease. Subsequently she was instrumental in the development of the British Association for Nursing in Cardiac Care (BANCC), an affiliated group to the British Cardiovascular Society, and was President of BANCC until 2003. Jill has served on a number of expert committees both nationally and internationally. Currently she sits on the Executive committee of the board of the European Heart Failure Association of the ESC. Dr Riley also reviews the evidence on the organisation of care and monitoring for the NHS evidence update on Heart Failure and sits on the cardiovascular strategic leadership group for NHS London where she co-chairs the heart failure subgroup.
Dr Riley has co-authored a text on cardiothoracic nursing and contributed to a number of other text books and publications. She is an associate editor for the European Journal of Heart Failure and sits on the editorial board of the European Journal of Cardiovascular Nursing and on the British Journal of Cardiac Nursing.
Area of expertise: cardiovascular disease in pregnancy and postpartum is one of her main areas of clinical and pathophysiological research
Prof. Karen Sliwa, MD, PhD, FESC, FACC, DTM & H- is the Director of the Hatter Institute for Cardiovascular Research in Africa (www.hatter.uct.ac.za), University of Cape Town, South Africa.Born in Germany, studying Medicine, undergoing training as a physician and cardiologist in a number of countries, she lives in South Africa since 1992.
Clinically her interests are in heart failure, rheumatic heart disease and all aspects of cardiovascular disease in pregnancy and postpartum. Her research spans from basic science to clinical studies to population studies. She has designed a number of innovative research programs and leveraged funding for several major research projects, not only in South Africa and the rest of Africa, but also internationally. She has published more than 200 articles and her work is highly cited.
In recognition of her work Prof Sliwa has received several prestigious awards.
Karen Sliwa serves on a number of editorial boards and is also an editorial consultant to ‘The Lancet’. Furthermore, she is the past president of the South African Heart Association, serves on the board of the South African Heart Failure Society (Hefssa; www.hefssa.org), which was established under her leadership 2005. She also president elect World Heart Federation ( 2017-2019),a member of the European Cardiac Society International Affairs committee and is board member of the Pan African Society of Cardiology.
Karl Swedberg is Senior Professor of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden and Professor of Cardiology, National Heart and Lung Institute, Imperial College, London. His research interests include beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs) and their effects on heart failure (HF) and myocardial infarction (MI), neuroendocrine activation in HF and the treatment of chronic HF. Professor Swedberg was the first to report on the survival benefits of a beta-blocker (1979), ACEI (1987) and angiotensin receptor blocker (2003) in chronic HF. He has published widely, including over 320 original research papers and 25 textbook chapters. Professor Swedberg was included in the 2016 listing of Highly Cited Researchers by Thomson-Reuters. In addition, he has been a steering committee member for numerous outcome trials in HF and MI and is a member of the Executive Committee for the PARADIGM-HF trial.
Professor Swedberg received the 2004 Kaufman Award from Cleveland Clinics (USA) for his HF research, the European Society of Cardiology Gold Medal 2007 for his outstanding contributions to the cardiovascular field and in 2016 the Lifetime Achievement Award from HFA. He has been an Honorary Member of the Thai Heart Association since 2007, the Swedish Society of Cardiology since 2008, and the Japan Circulatory Society since 2009. In addition, Professor Swedberg was Editor-in-Chief of European Journal of Heart Failure from 2005 to 2009. He is associate Editor of the European Heart Journal since 2012.
Faiez Zannad, MD, PhD, FESC is Professor of Therapeutics at the University of Lorraine in Nancy, France. Cardiologist and heart failure specialist, PhD in clinical pharmacology (Oxford, UK). Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux”, Nancy. Professor Zannad leads two EU FP7 granted programs: HOMAGE (omics biomarkers for mechanistic phenotyping and prediction of drug response [www.homage-hf.eu]) and FIBROTARGETS (fibrosis as a biotarget [www.fibrotargets.eu]). As the primary investigator or member of oversight committees in major clinical trials, he pioneers and/or made significant contributions to evidence-based heart failure therapy, mainly mineralocorticoid receptor antagonists (RALES, EPHESUS, EMPHASIS-HF), and beta-blockers (CIBIS) as well as in major comorbid diseases such as sleep disordered breathing (SERVE-HF), autonomic nervous dysfunction (NECTAR-HF, BEAT-HF), and diabetes (EXAMINE, EMPEROR), chronic kidney disease (FOSIDIAL, AURORA, ALCHEMIST), in diabetes (EXAMINE, EMPEROR), thrombosis in heart failure (COMMANDER-HF). He served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. He is the founder and is currently organizing the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think tank gathring dedicated to the science of clinical trials, with meetings in Paris, Washignton DC, Middle East and Asia.
© 2017 European Society of Cardiology. All rights reserved